Phase III results put obinutuzumab in line for approval ...

Marie Hindee experienced a breakthrough in her 15-year battle with chronic lymphocytic leukemia and small lymphocytic lymphoma after undergoing a cutting-edge therapy at Corewell Health Beaumont ...

The pharma giant has raised its dividends annually for 54 consecutive years. AbbVie has a large pipeline of mid- and late-stage drug candidates. 10 stocks we like better than AbbVie › There were times ...

New research suggests childhood cancer survivors may experience accelerated biological aging from treatments, potentially ...

Psoriasis is more than a skin condition: It’s a chronic autoimmune disease that involves systemic inflammation. There’s also evidence that the skin condition may be associated with a higher risk of ...

Organizers have announced that Jamie Campbell, who announces Blue Jays baseball games on Sportsnet, will present as the event’s keynote speaker. Campbell is known for uttering his catchphrase, “He hit ...

Fred Hutch Cancer Center scientists have developed an experimental strategy to give genetically engineered CAR T cells help they'd normally find within lymph nodes — but on the go, within the tumor.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that a detailed analysis of the Phase III ALLEGORY trial of Gazyva® (obinutuzumab) in adults with systemic lupus ...

A “living drug” was developed as a cancer treatment. Now it is showing promise for conditions, such as lupus and multiple sclerosis, that have long been considered incurable.